
    
      ECLA is a phase II, multicenter study testing sub cutaneous cladribine 0.1mg/kg/j during 5
      days, administrated every month for 4 courses, in symptomatic adult patients with pulmonary
      Langerhans cell histiocytosis and impairment of lung function patients.
    
  